{
  "prompt": {
    "prompt": "Original Transcript:\nSITUATION: 35-year-old G4P2+1 at 28+5 weeks gestation with major placenta previa and recent bleeding episode requiring management\n\nBACKGROUND: Mrs Ahmed has known complete placenta previa diagnosed at 20-week anomaly scan, where placenta was noted to completely cover the cervical os. She has been managed with pelvic rest and regular monitoring. Yesterday evening she experienced sudden onset bright red vaginal bleeding, described as 'heavy like a heavy period' lasting approximately 20 minutes before settling. No associated pain, no contractions, good fetal movements felt. This is her second bleeding episode - first was at 24 weeks requiring overnight observation. Obstetric history: 2 previous caesarean sections (emergency then elective), 1 first trimester miscarriage requiring ERPC. Significant risk factors for placenta previa include previous uterine surgery and maternal age. She has been compliant with activity restrictions and regular antenatal care.\n\nASSESSMENT: On examination, patient appears well, slightly anxious about bleeding. Vital signs stable: BP 118/72 mmHg, HR 88 bpm, temp 36.6°C. Abdomen soft, non-tender, fundal height 29cm. No current bleeding visible, small clots in pad from earlier episode. No abdominal pain or uterine tenderness. CTG shows reassuring fetal heart rate pattern with baseline 145 bpm, good variability, no decelerations. Recent ultrasound confirms complete placenta previa with placental edge 0mm from internal os. No evidence of placental abruption. Hemoglobin 10.8 g/dL (down from 11.4 g/dL last month), other bloods normal. Kleihauer-Betke test negative (Rh positive mother).\n\nRECOMMENDATION: Admission for observation and surveillance given significant bleeding episode. IV access established, cross-match for 4 units of blood. Antenatal corticosteroids administered for fetal lung maturity given risk of early delivery. Strict bed rest initially, then gradual mobilization if no further bleeding. Daily monitoring with CTG and maternal observations. Serial hemoglobin monitoring. Emergency caesarean section if further significant bleeding occurs. Elective caesarean section planned for 36-37 weeks if no further complications. Anesthetic consultation arranged given high-risk nature and potential for emergency delivery. Blood transfusion service informed of high-risk patient.\n\nGuideline Analysis:\n### Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document the specific corticosteroid regimen administered (dexamethasone phosphate or betamethasone sodium phosphate/acetate mix) and the timing of administration relative to potential delivery.  \n   Reason: The guideline specifies the optimal dose and route (24mg dexamethasone phosphate or 24mg betamethasone sodium phosphate/acetate mix IM) and emphasizes effectiveness within 48 hours prior to birth (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \n\n2. **Improved patient advice** - Provide explicit counseling to the patient about the benefits (reduced neonatal respiratory distress and mortality) and risks (potential neonatal hypoglycemia, long-term metabolic effects) of antenatal corticosteroids.  \n   Reason: The guideline highlights the importance of informed discussions, especially regarding risks in late preterm (35+0 to 36+6 weeks) and special populations (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \n\n### Somewhat Important Recommendations\n1. **Different management plan** - Consider serial hemoglobin monitoring more frequently (e.g., every 12–24 hours) given the drop from 11.4 to 10.8 g/dL and active bleeding risk.  \n   Reason: While not explicitly stated in the guideline, close monitoring aligns with general principles of managing antepartum hemorrhage and anemia (implied in guideline sections on high-risk pregnancies).  \n\n2. **Additional information needed** - Document whether a discussion occurred about the potential need for repeat corticosteroids if delivery is delayed beyond 7 days.  \n   Reason: The guideline notes limited evidence for repeat courses but recommends considering them if the risk of preterm birth persists (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \n\n### Less Important Recommendations\n1. **Improved patient advice** - Offer written information or support group links about placenta previa and corticosteroids.  \n   Reason: The guideline mentions providing support resources, though this is not critical for immediate management (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \n\n2. **Additional information needed** - Document fetal growth percentile (if available) to assess small-for-gestational-age risk, as corticosteroids may have limited evidence in this population.  \n   Reason: The guideline notes uncertainty about corticosteroids in growth-restricted infants (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \n\n### Unimportant Recommendations\n1. **Different management plan** - Consider adding a note about anesthetic consultation timing (e.g., \"within 24 hours\") for clarity.  \n   Reason: While useful for workflow, this is not guideline-mandated and does not impact safety.  \n\n---  \n**Summary**: The note largely aligns with the guideline, but critical gaps include documentation of the corticosteroid regimen and patient counseling. Close monitoring and explicit discussions about risks/benefits are prioritized.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 163 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\n\n\nFull Guideline Content:\nAntenatal corticosteroids given within seven days prior to preterm birth reduce perinatal and neonatal death and respiratory distress syndrome. For women undergoing planned caesarean birth between 37+0 and 38+6 weeks, an informed discussion should take place about the potential risks and benefits of corticosteroids. Corticosteroids should be offered to women between 24+0 and 34+6 weeks' gestation in whom imminent preterm birth is anticipated. Women with twins and triplets should also be offered corticosteroids. Birth should not be delayed for corticosteroids if it impacts the health of the woman or baby. Antenatal corticosteroids should be offered to women with preterm prelabour rupture of membranes. Corticosteroids reduce neonatal death when given within 48 hours prior to birth, and benefits are still seen if given within 24 hours of birth.\n\nAntenatal corticosteroids should be considered for women at risk of preterm birth between 35+0 to 36+6 weeks gestation. Steroids have short-term respiratory benefits for the neonate but may increase the risk of neonatal hypoglycemia. The use of corticosteroids in late preterm birth should be carefully weighed for its risks and benefits. In multiple pregnancies, targeted corticosteroids for early birth should be considered, as there is little evidence of benefit in twins compared to singletons. Women with diabetes should not be excluded from receiving corticosteroids, but additional insulin and close monitoring are recommended. Antenatal corticosteroids should not delay birth if it is necessary for the health of the woman or baby. In pregnancies complicated by fetal growth restriction, pre-eclampsia, or antepartum hemorrhage, corticosteroids may be considered if imminent preterm birth is likely. Women should be informed about the lack of evidence for the use of corticosteroids in small-for-gestational-age babies.\n\nAntenatal corticosteroids should be offered to women with PPROM who are at increased risk of preterm birth. There is limited evidence to recommend repeat courses of antenatal corticosteroids if a woman remains at imminent risk of preterm birth seven days after administration. The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly. Antenatal corticosteroids are most effective when given within 48 hours prior to birth, with benefits seen within 24 hours of birth. They are most effective in reducing RDS in pregnancies that birth between 24 hours and 7 days of administration of the second dose.\n\nAntenatal corticosteroids have shown significant reductions in cases of RDS and cerebroventricular hemorrhage among infants born within specific time frames after administration. There is a reduction in fetal and neonatal death for births within 24 hours to seven days after administration. However, caution is advised in interpreting the data due to limitations in subgroup analyses. Population-based cohort studies support the early effects of antenatal corticosteroids, with the largest effect seen 24 hours to seven days after the first injection. Concerns about potential risks to both women and babies include effects on maternal blood glucose levels, fetal growth, neonatal hypoglycemia, long-term metabolic and neurological consequences, and potential impacts on brain development. WHO recommends offering antenatal corticosteroids only when minimum standards of maternal and neonatal hospital services are available.\n\nAntenatal corticosteroids should not be delayed in serious maternal or fetal conditions. In the presence of systemic infection, the use of corticosteroids should be carefully balanced due to the risk of exacerbating the infection. Repeat courses of corticosteroids may not reduce serious morbidity but can lead to smaller babies. The maximum number of corticosteroid courses in pregnancy should not exceed three. Research is needed to determine the effectiveness of corticosteroids in various conditions and to investigate potential off-target effects. Recommendations for future research include determining the effectiveness of corticosteroids in reducing neonatal morbidity in elective caesarean births at term and investigating the safety and effectiveness of steroids in multiple pregnancies and women with diabetes. Auditable topics include discussions about corticosteroids in planned caesarean births and the proportion of women offered corticosteroids for preterm birth. Support groups and useful links are provided for further information.\n\nAntenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. Managing hyperglycaemia during antenatal steroid administration, labour, and birth in pregnant women with diabetes. Should antenatal corticosteroids be considered in women with gestational diabetes before planned late gestation caesarean section. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysis. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes. Multiple courses of antenatal corticosteroid therapy in patients with preterm premature rupture of membranes. Neonatal sepsis after betamethasone administration to patients with preterm premature rupture of membranes. Length of latency with preterm premature rupture of membranes before 32 weeks' gestation. Duration of the latency period in preterm premature rupture of the membranes. Preterm premature rupture of the membranes. Length of latency with preterm premature rupture of membranes. Association of fetal growth restriction with neurocognitive function after repeated antenatal betamethasone treatment vs placebo. Antenatal corticosteroids for preterm premature rupture of membranes: single or repeat course. The clinical use of corticosteroids in pregnancy. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Maternal intramuscular dexamethasone versus betamethasone before preterm birth. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Antenatal dexamethasone for early preterm birth in low-resource countries. Antenatal corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Antenatal corticosteroid therapy and blood pressure at 14 years of age in preterm children. Neurodevelopmental disorders among term infants exposed to antenatal corticosteroids during pregnancy. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. Persistent effects of antenatal synthetic glucocorticoids on endocrine stress reactivity from childhood to adolescence. Long-term impacts of prenatal synthetic glucocorticoids exposure on functional brain correlates of cognitive monitoring in adolescence. Prenatal betamethasone exposure and psychopathology risk in extremely low birth weight survivors in the third and fourth decades of life. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries.\n\nPlease extract actionable suggestions from this analysis and format them as specified. For each suggestion, include detailed context with relevant quoted text from the guideline to help the user understand the reasoning behind the recommendation.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nCRITICAL CLINICAL REASONING REQUIREMENTS:\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\n- Apply the fundamental principle: \"Will this investigation or intervention change management or improve patient care in this specific scenario?\"\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\n\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\n- Consider whether additional investigations would actually change the management approach\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"detailed explanation of why this change is suggested, including relevant quoted text from the guideline in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nImportant guidelines for context field:\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\n- Include specific quoted text from the guideline using quotation marks (e.g., \"According to the guideline: 'All women should receive screening for...'\")\n- Reference specific guideline recommendations or requirements\n- Explain the clinical rationale behind the suggestion\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\n- Make the context informative and educational\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis AND clinically appropriate for the specific scenario\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Prioritize suggestions based on clinical importance and appropriateness\n- If no clinically appropriate suggestions can be made, return {\"suggestions\": []}\n- When in doubt about appropriateness, err on the side of NOT making the suggestion",
    "transcript_length": 2335,
    "analysis_length": 3369,
    "guideline_id": "bjog-2022-stock-antenatal-corticosteroids-to-reduce-neonatal-morbidity-and-mortality-pdf",
    "guideline_title": "Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Missing: specific corticosteroid regimen documentation\",\n      \"suggestedText\": \"Document the specific corticosteroid regimen administered (dexamethasone phosphate 24mg IM or betamethasone sodium phosphate/acetate mix 24mg IM) and timing relative to potential delivery\",\n      \"context\": \"The guideline specifies: 'The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly.' This documentation is critical for this patient at 28+5 weeks with placenta previa and bleeding, as it confirms proper administration and timing for maximal fetal benefit if delivery occurs within 7 days.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Optimum dose and route of administration\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Gap: no documentation of counseling about corticosteroid risks/benefits\",\n      \"suggestedText\": \"Document detailed counseling regarding: 1) Benefits (reduced neonatal respiratory distress and mortality) 2) Risks (neonatal hypoglycemia, potential long-term metabolic effects) 3) Timeframe of effectiveness (maximal benefit if delivery occurs 24h-7d post-administration)\",\n      \"context\": \"The guideline emphasizes informed discussions: 'Women should be informed about...potential risks and benefits of corticosteroids.' For this high-risk patient with recurrent bleeding, explicit documentation of counseling is essential given the significant neonatal benefits (reduced RDS and mortality) and potential risks that require monitoring.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Informed discussion requirements\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Serial hemoglobin monitoring\",\n      \"suggestedText\": \"Serial hemoglobin monitoring every 12-24 hours initially given active bleeding risk and drop from 11.4 to 10.8 g/dL\",\n      \"context\": \"While not explicitly stated in the corticosteroid guideline, this modification aligns with general high-risk pregnancy management principles for placenta previa with active bleeding. The hemoglobin drop indicates significant blood loss, warranting closer monitoring in this specific case to guide potential transfusion needs.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Implied in high-risk pregnancy management\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: discussion of potential repeat corticosteroids if delivery delayed >7 days\",\n      \"suggestedText\": \"Document discussion about potential need for repeat corticosteroids if delivery is delayed beyond 7 days while still at high preterm birth risk\",\n      \"context\": \"The guideline notes: 'There is limited evidence to recommend repeat courses...if a woman remains at imminent risk of preterm birth seven days after administration.' For this patient with recurrent bleeding episodes, this discussion is clinically relevant as she may remain at high risk for preterm delivery beyond the initial 7-day window of corticosteroid effectiveness.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Repeat courses consideration\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Missing: documentation of fetal growth assessment\",\n      \"suggestedText\": \"Document fetal growth percentile from most recent ultrasound to assess for growth restriction\",\n      \"context\": \"The guideline specifies: 'Women should be informed about the lack of evidence for the use of corticosteroids in small-for-gestational-age babies.' While not urgent, documenting growth status is relevant for this high-risk pregnancy as it may influence counseling about corticosteroid efficacy and neonatal monitoring needs.\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Special populations considerations\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-19T12-01-36",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nSITUATION: 35-year-old G4P2+1 at 28+5 weeks gestation with major placenta previa and recent bleeding episode requiring management\\n\\nBACKGROUND: Mrs Ahmed has known complete placenta previa diagnosed at 20-week anomaly scan, where placenta was noted to completely cover the cervical os. She has been managed with pelvic rest and regular monitoring. Yesterday evening she experienced sudden onset bright red vaginal bleeding, described as 'heavy like a heavy period' lasting approximately 20 minutes before settling. No associated pain, no contractions, good fetal movements felt. This is her second bleeding episode - first was at 24 weeks requiring overnight observation. Obstetric history: 2 previous caesarean sections (emergency then elective), 1 first trimester miscarriage requiring ERPC. Significant risk factors for placenta previa include previous uterine surgery and maternal age. She has been compliant with activity restrictions and regular antenatal care.\\n\\nASSESSMENT: On examination, patient appears well, slightly anxious about bleeding. Vital signs stable: BP 118/72 mmHg, HR 88 bpm, temp 36.6°C. Abdomen soft, non-tender, fundal height 29cm. No current bleeding visible, small clots in pad from earlier episode. No abdominal pain or uterine tenderness. CTG shows reassuring fetal heart rate pattern with baseline 145 bpm, good variability, no decelerations. Recent ultrasound confirms complete placenta previa with placental edge 0mm from internal os. No evidence of placental abruption. Hemoglobin 10.8 g/dL (down from 11.4 g/dL last month), other bloods normal. Kleihauer-Betke test negative (Rh positive mother).\\n\\nRECOMMENDATION: Admission for observation and surveillance given significant bleeding episode. IV access established, cross-match for 4 units of blood. Antenatal corticosteroids administered for fetal lung maturity given risk of early delivery. Strict bed rest initially, then gradual mobilization if no further bleeding. Daily monitoring with CTG and maternal observations. Serial hemoglobin monitoring. Emergency caesarean section if further significant bleeding occurs. Elective caesarean section planned for 36-37 weeks if no further complications. Anesthetic consultation arranged given high-risk nature and potential for emergency delivery. Blood transfusion service informed of high-risk patient.\\n\\nGuideline Analysis:\\n### Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document the specific corticosteroid regimen administered (dexamethasone phosphate or betamethasone sodium phosphate/acetate mix) and the timing of administration relative to potential delivery.  \\n   Reason: The guideline specifies the optimal dose and route (24mg dexamethasone phosphate or 24mg betamethasone sodium phosphate/acetate mix IM) and emphasizes effectiveness within 48 hours prior to birth (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \\n\\n2. **Improved patient advice** - Provide explicit counseling to the patient about the benefits (reduced neonatal respiratory distress and mortality) and risks (potential neonatal hypoglycemia, long-term metabolic effects) of antenatal corticosteroids.  \\n   Reason: The guideline highlights the importance of informed discussions, especially regarding risks in late preterm (35+0 to 36+6 weeks) and special populations (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \\n\\n### Somewhat Important Recommendations\\n1. **Different management plan** - Consider serial hemoglobin monitoring more frequently (e.g., every 12–24 hours) given the drop from 11.4 to 10.8 g/dL and active bleeding risk.  \\n   Reason: While not explicitly stated in the guideline, close monitoring aligns with general principles of managing antepartum hemorrhage and anemia (implied in guideline sections on high-risk pregnancies).  \\n\\n2. **Additional information needed** - Document whether a discussion occurred about the potential need for repeat corticosteroids if delivery is delayed beyond 7 days.  \\n   Reason: The guideline notes limited evidence for repeat courses but recommends considering them if the risk of preterm birth persists (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \\n\\n### Less Important Recommendations\\n1. **Improved patient advice** - Offer written information or support group links about placenta previa and corticosteroids.  \\n   Reason: The guideline mentions providing support resources, though this is not critical for immediate management (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \\n\\n2. **Additional information needed** - Document fetal growth percentile (if available) to assess small-for-gestational-age risk, as corticosteroids may have limited evidence in this population.  \\n   Reason: The guideline notes uncertainty about corticosteroids in growth-restricted infants (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  \\n\\n### Unimportant Recommendations\\n1. **Different management plan** - Consider adding a note about anesthetic consultation timing (e.g., \\\"within 24 hours\\\") for clarity.  \\n   Reason: While useful for workflow, this is not guideline-mandated and does not impact safety.  \\n\\n---  \\n**Summary**: The note largely aligns with the guideline, but critical gaps include documentation of the corticosteroid regimen and patient counseling. Close monitoring and explicit discussions about risks/benefits are prioritized.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 163 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\\n\\n\\nFull Guideline Content:\\nAntenatal corticosteroids given within seven days prior to preterm birth reduce perinatal and neonatal death and respiratory distress syndrome. For women undergoing planned caesarean birth between 37+0 and 38+6 weeks, an informed discussion should take place about the potential risks and benefits of corticosteroids. Corticosteroids should be offered to women between 24+0 and 34+6 weeks' gestation in whom imminent preterm birth is anticipated. Women with twins and triplets should also be offered corticosteroids. Birth should not be delayed for corticosteroids if it impacts the health of the woman or baby. Antenatal corticosteroids should be offered to women with preterm prelabour rupture of membranes. Corticosteroids reduce neonatal death when given within 48 hours prior to birth, and benefits are still seen if given within 24 hours of birth.\\n\\nAntenatal corticosteroids should be considered for women at risk of preterm birth between 35+0 to 36+6 weeks gestation. Steroids have short-term respiratory benefits for the neonate but may increase the risk of neonatal hypoglycemia. The use of corticosteroids in late preterm birth should be carefully weighed for its risks and benefits. In multiple pregnancies, targeted corticosteroids for early birth should be considered, as there is little evidence of benefit in twins compared to singletons. Women with diabetes should not be excluded from receiving corticosteroids, but additional insulin and close monitoring are recommended. Antenatal corticosteroids should not delay birth if it is necessary for the health of the woman or baby. In pregnancies complicated by fetal growth restriction, pre-eclampsia, or antepartum hemorrhage, corticosteroids may be considered if imminent preterm birth is likely. Women should be informed about the lack of evidence for the use of corticosteroids in small-for-gestational-age babies.\\n\\nAntenatal corticosteroids should be offered to women with PPROM who are at increased risk of preterm birth. There is limited evidence to recommend repeat courses of antenatal corticosteroids if a woman remains at imminent risk of preterm birth seven days after administration. The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly. Antenatal corticosteroids are most effective when given within 48 hours prior to birth, with benefits seen within 24 hours of birth. They are most effective in reducing RDS in pregnancies that birth between 24 hours and 7 days of administration of the second dose.\\n\\nAntenatal corticosteroids have shown significant reductions in cases of RDS and cerebroventricular hemorrhage among infants born within specific time frames after administration. There is a reduction in fetal and neonatal death for births within 24 hours to seven days after administration. However, caution is advised in interpreting the data due to limitations in subgroup analyses. Population-based cohort studies support the early effects of antenatal corticosteroids, with the largest effect seen 24 hours to seven days after the first injection. Concerns about potential risks to both women and babies include effects on maternal blood glucose levels, fetal growth, neonatal hypoglycemia, long-term metabolic and neurological consequences, and potential impacts on brain development. WHO recommends offering antenatal corticosteroids only when minimum standards of maternal and neonatal hospital services are available.\\n\\nAntenatal corticosteroids should not be delayed in serious maternal or fetal conditions. In the presence of systemic infection, the use of corticosteroids should be carefully balanced due to the risk of exacerbating the infection. Repeat courses of corticosteroids may not reduce serious morbidity but can lead to smaller babies. The maximum number of corticosteroid courses in pregnancy should not exceed three. Research is needed to determine the effectiveness of corticosteroids in various conditions and to investigate potential off-target effects. Recommendations for future research include determining the effectiveness of corticosteroids in reducing neonatal morbidity in elective caesarean births at term and investigating the safety and effectiveness of steroids in multiple pregnancies and women with diabetes. Auditable topics include discussions about corticosteroids in planned caesarean births and the proportion of women offered corticosteroids for preterm birth. Support groups and useful links are provided for further information.\\n\\nAntenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. Managing hyperglycaemia during antenatal steroid administration, labour, and birth in pregnant women with diabetes. Should antenatal corticosteroids be considered in women with gestational diabetes before planned late gestation caesarean section. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysis. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes. Multiple courses of antenatal corticosteroid therapy in patients with preterm premature rupture of membranes. Neonatal sepsis after betamethasone administration to patients with preterm premature rupture of membranes. Length of latency with preterm premature rupture of membranes before 32 weeks' gestation. Duration of the latency period in preterm premature rupture of the membranes. Preterm premature rupture of the membranes. Length of latency with preterm premature rupture of membranes. Association of fetal growth restriction with neurocognitive function after repeated antenatal betamethasone treatment vs placebo. Antenatal corticosteroids for preterm premature rupture of membranes: single or repeat course. The clinical use of corticosteroids in pregnancy. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Maternal intramuscular dexamethasone versus betamethasone before preterm birth. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Antenatal dexamethasone for early preterm birth in low-resource countries. Antenatal corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Antenatal corticosteroid therapy and blood pressure at 14 years of age in preterm children. Neurodevelopmental disorders among term infants exposed to antenatal corticosteroids during pregnancy. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. Persistent effects of antenatal synthetic glucocorticoids on endocrine stress reactivity from childhood to adolescence. Long-term impacts of prenatal synthetic glucocorticoids exposure on functional brain correlates of cognitive monitoring in adolescence. Prenatal betamethasone exposure and psychopathology risk in extremely low birth weight survivors in the third and fourth decades of life. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries.\\n\\nPlease extract actionable suggestions from this analysis and format them as specified. For each suggestion, include detailed context with relevant quoted text from the guideline to help the user understand the reasoning behind the recommendation.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nCRITICAL CLINICAL REASONING REQUIREMENTS:\\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\\n- Apply the fundamental principle: \\\"Will this investigation or intervention change management or improve patient care in this specific scenario?\\\"\\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\\n\\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\\n- Consider whether additional investigations would actually change the management approach\\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"detailed explanation of why this change is suggested, including relevant quoted text from the guideline in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nImportant guidelines for context field:\\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\\n- Include specific quoted text from the guideline using quotation marks (e.g., \\\"According to the guideline: 'All women should receive screening for...'\\\")\\n- Reference specific guideline recommendations or requirements\\n- Explain the clinical rationale behind the suggestion\\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\\n- Make the context informative and educational\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis AND clinically appropriate for the specific scenario\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Prioritize suggestions based on clinical importance and appropriateness\\n- If no clinically appropriate suggestions can be made, return {\\\"suggestions\\\": []}\\n- When in doubt about appropriateness, err on the side of NOT making the suggestion\",\n  \"transcript_length\": 2335,\n  \"analysis_length\": 3369,\n  \"guideline_id\": \"bjog-2022-stock-antenatal-corticosteroids-to-reduce-neonatal-morbidity-and-mortality-pdf\",\n  \"guideline_title\": \"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Missing: specific corticosteroid regimen documentation\",\n      \"suggestedText\": \"Document the specific corticosteroid regimen administered (dexamethasone phosphate 24mg IM or betamethasone sodium phosphate/acetate mix 24mg IM) and timing relative to potential delivery\",\n      \"context\": \"The guideline specifies: 'The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly.' This documentation is critical for this patient at 28+5 weeks with placenta previa and bleeding, as it confirms proper administration and timing for maximal fetal benefit if delivery occurs within 7 days.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Optimum dose and route of administration\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Gap: no documentation of counseling about corticosteroid risks/benefits\",\n      \"suggestedText\": \"Document detailed counseling regarding: 1) Benefits (reduced neonatal respiratory distress and mortality) 2) Risks (neonatal hypoglycemia, potential long-term metabolic effects) 3) Timeframe of effectiveness (maximal benefit if delivery occurs 24h-7d post-administration)\",\n      \"context\": \"The guideline emphasizes informed discussions: 'Women should be informed about...potential risks and benefits of corticosteroids.' For this high-risk patient with recurrent bleeding, explicit documentation of counseling is essential given the significant neonatal benefits (reduced RDS and mortality) and potential risks that require monitoring.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Informed discussion requirements\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Serial hemoglobin monitoring\",\n      \"suggestedText\": \"Serial hemoglobin monitoring every 12-24 hours initially given active bleeding risk and drop from 11.4 to 10.8 g/dL\",\n      \"context\": \"While not explicitly stated in the corticosteroid guideline, this modification aligns with general high-risk pregnancy management principles for placenta previa with active bleeding. The hemoglobin drop indicates significant blood loss, warranting closer monitoring in this specific case to guide potential transfusion needs.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Implied in high-risk pregnancy management\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: discussion of potential repeat corticosteroids if delivery delayed >7 days\",\n      \"suggestedText\": \"Document discussion about potential need for repeat corticosteroids if delivery is delayed beyond 7 days while still at high preterm birth risk\",\n      \"context\": \"The guideline notes: 'There is limited evidence to recommend repeat courses...if a woman remains at imminent risk of preterm birth seven days after administration.' For this patient with recurrent bleeding episodes, this discussion is clinically relevant as she may remain at high risk for preterm delivery beyond the initial 7-day window of corticosteroid effectiveness.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Repeat courses consideration\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Missing: documentation of fetal growth assessment\",\n      \"suggestedText\": \"Document fetal growth percentile from most recent ultrasound to assess for growth restriction\",\n      \"context\": \"The guideline specifies: 'Women should be informed about the lack of evidence for the use of corticosteroids in small-for-gestational-age babies.' While not urgent, documenting growth status is relevant for this high-risk pregnancy as it may influence counseling about corticosteroid efficacy and neonatal monitoring needs.\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Special populations considerations\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 3330\nCompletion tokens: 819\nTotal tokens: 4149\nEstimated cost: $0.002074",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 3330,
    "completion_tokens": 819,
    "total_tokens": 4149,
    "estimated_cost_usd": 0.0020745
  }
}